Ars Pharmaceuticals Inc

Company Overview

Business Model: ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the commercialization and development of neffy (known as EURneffy in the European Union and United Kingdom, and 优敏速 in China). neffy is a needle-free intranasal epinephrine product designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. The company generates revenue through direct product sales in the U.S. and through licensing and collaboration agreements with international partners, which include non-refundable upfront fees, clinical, regulatory, and commercial milestone payments, and royalties or transfer prices on net sales. The company is also developing neffy for additional indications, such as chronic urticaria.

Market Position: neffy is the first and only U.S. Food and Drug Administration ("FDA") and European Commission ("EC")-approved needle-free epinephrine product, representing the first new delivery method for epinephrine in over 35 years. It is approved in the U.S., EU, U.K., Japan, Australia, and China, and is under regulatory review in Canada, covering countries representing approximately 98% of current global epinephrine autoinjector sales. The U.S. market opportunity for neffy is estimated to be significant, with approximately 3.2 million patients currently filling epinephrine autoinjector prescriptions representing an estimated $1.8 billion in annual U.S. net sales based on 2025 unit volume. The broader addressable market, including patients who do not fill prescriptions or are undiagnosed, is estimated at $3.5 billion to $7.0 billion in annual net sales. Key differentiators include its needle-free, easy-to-use, pocket-sized, and highly reliable nasal spray design, absence of needle-related injury risk, reduced hesitation to dose, and improved stability (30 months for 2mg, 24 months for 1mg at room temperature, and up to 3 months at 50°C). Real-world data from the neffy experience program indicates approximately 90% effectiveness with a single dose, consistent with epinephrine injection.

Recent Strategic Developments:

• August 2024: FDA approved neffy 2 mg for adults and children weighing 30 kg or greater.
• September 2024: Commercial launch of neffy 2 mg in the United States.
• March 2025: FDA approved neffy 1 mg for patients four years of age and older weighing 15 kg to less than 30 kg.
• May 2025: Commercial launch of neffy 1 mg in the U.S. and initiation of a co-promotion U.S. sales force with ALK-Abelló, Inc. targeting pediatricians.
• June 2025: EURneffy 2 mg launched in Germany through collaboration with ALK-Abelló A/S.
• October 2025: EURneffy 2 mg launched in the U.K. through collaboration with ALK-Abelló A/S.
• September 2025: neffy 2 mg and 1 mg approved in Japan, with commercial launch expected in Q1 2026 by Alfresa Pharma Corporation.
• December 2025: neffy 2 mg and 1 mg approved in Australia, with commercial launch initiated in February 2026 by Seqirus Pty Ltd.
• December 2025: 优敏速 (neffy 2 mg) approved in China, with commercial launch expected in H1 2026 by Pediatrix Therapeutics, Inc.
• January 2026: The Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") adopted a positive opinion recommending marketing authorization in the EU for EURneffy 1 mg.
• Q2 2026 (expected): Regulatory decision for neffy 2 mg in Canada, with commercial launch expected later in 2026 by ALK-Abelló A/S if approved.
• November 2025: Launched getneffy.com virtual prescriber website and direct-to-consumer advertising to minimize physician and patient burden.
• Q2 2025: Initiated a Phase 2b randomized, placebo-controlled outpatient clinical trial for chronic spontaneous urticaria patients. Interim data is anticipated in H2 2026, with potential initiation of a single pivotal efficacy study in mid-2027.

Geographic Footprint:

• Primary Operational Regions: United States (corporate headquarters in San Diego, California).
• Key Markets (Approved/Launched): United States, European Union (Germany), United Kingdom, Japan, Australia, China.
• International Exposure (Partnerships/Review): Canada, New Zealand.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 75.8%
• Operating Margin: -212.9%
• Net Margin: -203.3%

Investment in Growth:

• R&D Expenditure: $13.2 million (15.7% of revenue)
• Capital Expenditures: $0.3 million
• Strategic Investments: $7.9 million in milestone obligations under license agreements; $6.0 million in corporate sponsorship payments.

Business Segment Analysis

ARS Pharmaceuticals, Inc. views its operations and manages its business as a single operating segment. However, revenue streams can be analyzed by source.

Product Revenue (U.S.)

Financial Performance:

• Revenue: $72.2 million (+889.0% YoY from $7.3 million in 2024).
• Operating Margin: Not directly calculable as segment operating expenses are not disaggregated by revenue source.
• Key Growth Drivers: U.S. commercial launch of neffy 2 mg (August 2024) and neffy 1 mg (May 2025); direct sales force of 106 individuals; co-promotion sales force of approximately 70 individuals with ALK-Abelló, Inc. targeting pediatricians (launched May 2025); getneffy.com virtual prescriber website (launched November 2025); branded direct-to-consumer marketing; neffy experience program (over 2,800 healthcare professionals enrolled by November 2024); increasing insurance coverage (approximately 93% overall commercial coverage, 57% without prior authorization; 8 of 50 Medicaid states covering without prior authorization); over 22,500 physicians prescribed neffy since launch (as of February 2026).

Product Portfolio:

• neffy 2 mg: Approved for emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing 30 kg or greater.
• neffy 1 mg: Approved for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients four years of age and older weighing 15 kg to less than 30 kg.

Market Dynamics:

• Targets approximately 3.2 million patients who currently fill epinephrine autoinjector prescriptions, 3.3 million who do not fill/renew, and 13.5 million diagnosed but not prescribed.
• Competitive positioning against existing epinephrine intra-muscular injectable products.

Revenue under Collaboration Agreements (Ex-U.S.)

Financial Performance:

• Revenue: $9.7 million (-88.1% YoY from $81.5 million in 2024).
• Operating Margin: Not directly calculable.
• Key Growth Drivers: Achievement of regulatory and commercial milestones from international partners; initial commercial sales and royalties in partnered territories.
• Breakdown (2025): $4.0 million from Pediatrix Therapeutics, Inc. (China); $2.6 million commercial milestone and $0.2 million royalties from ALK-Abelló A/S (ALK Territory ex-EEA); $2.0 million commercial milestone from Alfresa Pharma Corporation (Japan); $0.6 million regulatory/commercial milestones from Seqirus Pty Ltd. (Australia/New Zealand); $0.3 million from development and regulatory services for ALK-Abelló A/S.

Product Portfolio:

• EURneffy 2 mg: Launched in Germany (June 2025) and U.K. (October 2025) for emergency treatment of Type I allergic reactions in adults and children weighing 30 kg or greater.
• EURneffy 1 mg: Positive EMA CHMP opinion for children four years of age and older weighing 15 kg to less than 30 kg.
• neffy 2 mg and 1 mg: Approved in Japan (expected Q1 2026 launch), Australia (launched February 2026), and China (expected H1 2026 launch).

Market Dynamics:

• Commercialization through exclusive licensing and collaboration partners: ALK-Abelló A/S (Canada, EU, U.K., other unpartnered territories), Alfresa Pharma Corporation (Japan), Pediatrix Therapeutics, Inc. (China, Macau, Hong Kong, Taiwan), and Seqirus Pty Ltd. (Australia, New Zealand).
• ALK-Abelló A/S anticipates peak sales for neffy of approximately $425 million USD in Canada, the EU, and the U.K.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None.
• Dividend Payments: ARS Pharmaceuticals, Inc. has never declared or paid cash dividends and does not intend to do so for the foreseeable future, planning to retain future earnings to fund business development and growth.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position:

• Cash and Equivalents: $41.3 million (as of December 31, 2025)
• Total Debt: $100.0 million (Term A Loan principal outstanding as of December 31, 2025)
• Net Cash Position: -$58.7 million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Term Loans mature on September 29, 2030, with interest-only payments on a quarterly basis until maturity.
• Credit Agreement covenants include a minimum liquidity requirement of $25.0 million in unrestricted cash and cash equivalents, and limitations on incurring additional debt, creating liens, mergers and acquisitions, dividends, and transactions with affiliates. The company is currently in compliance with these covenants.

Cash Flow Generation:

• Operating Cash Flow: -$170.9 million (for the year ended December 31, 2025)
• Free Cash Flow: Not explicitly provided, but significantly negative given operating cash outflow and capital expenditures.
• Cash Conversion Metrics: Not explicitly detailed.

Operational Excellence

Production & Service Model:

• Manufacturing Approach: ARS Pharmaceuticals, Inc. relies entirely on third-party Contract Manufacturing Organizations ("CMOs") for the manufacture and warehousing of raw materials, drug substance, drug product, labeling, and packaging for neffy and its intranasal epinephrine technology product candidates.
• Operational Philosophy: Internal resources and third-party consultants manage CMO relationships.
• Product Stability: neffy 2 mg has a shelf-life of 30 months at room temperature, and neffy 1 mg has a shelf-life of 24 months at room temperature. neffy has demonstrated improved stability at high temperatures, meeting specifications for up to 3 months at 50°C (122°F).

Supply Chain Architecture: Key Suppliers & Partners:

• Active Pharmaceutical Ingredient (API): Cambrex Profarmco (Italy) for epinephrine API, with a commercial supply agreement in place. Multiple API sources are available.
• Absorption Enhancer: Intravail, licensed from Aegis Therapeutics, LLC, is purchased from Dr. Reddy Laboratories (India) and Inalco (Italy).
• Unit Dose Sprayer Device: Aptar Pharma (France, U.S.) and Silgan Dispensing Systems (Germany). Both manufacturers have sufficient capacity.
• Drug Product Manufacturing & Final Packaging: Renaissance Lakewood, LLC (Lakewood, New Jersey) serves as the primary source, with a commercial supply agreement in place. ARS Pharmaceuticals, Inc. is evaluating alternative sourcing options.

Facility Network:

• Manufacturing: Primarily Renaissance Lakewood, LLC (Lakewood, New Jersey).
• Research & Development: Not explicitly detailed as separate facilities.
• Distribution: Supported by a third-party logistics provider.

Operational Metrics:

• Not explicitly detailed beyond product stability and manufacturing capacity statements.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: A U.S. direct sales force of 106 individuals (sales representatives, key account managers, area sales managers, and national sales directors) targets high-volume prescribers, including allergists, pediatricians, and primary care physicians. The company plans to expand this internal sales force to approximately 150 individuals in Q2 2026.
• Channel Partners:
  • ALK-Abelló, Inc. (ALK U.S.): A co-promotion agreement launched in May 2025, deploying approximately 70 sales representatives to target up to 9,000 specified pediatricians and other prescribers in the U.S.
  • Wholesale Distributors and Pharmacies: These are the primary channels for distributing products to healthcare providers in the U.S.
  • International Partners: Exclusive licensing and collaboration agreements are in place with Alfresa Pharma Corporation (Japan), Pediatrix Therapeutics, Inc. (China, Macau, Hong Kong, Taiwan), Seqirus Pty Ltd. (Australia, New Zealand), and ALK-Abelló A/S (Canada, EU, U.K., and other unpartnered territories).
• Digital Platforms: The getneffy.com virtual prescriber website, launched in November 2025, offers patients the option to obtain a neffy prescription the same day with a free virtual healthcare provider visit.
• Marketing: Multi-channel branded direct-to-consumer advertising (streaming platforms, traditional broadcast and cable television, consumer-facing digital channels, social media, paid search) initiated in May 2025, with linear television advertising starting in June 2025. Non-personal promotion with healthcare providers and disease awareness campaigns with advocacy groups are also utilized.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: In 2025, five customers accounted for 82% of accounts receivable (each ranging from 12% to 21%), and four customers accounted for 79% of gross product sales (each ranging from 15% to 22%).
• Strategic Partnerships: Key partnerships include ALK-Abelló, Inc. (U.S. co-promotion), Alfresa Pharma Corporation (Japan), Pediatrix Therapeutics, Inc. (China), Seqirus Pty Ltd. (Australia/New Zealand), ALK-Abelló A/S (ex-U.S. territories), and a corporate sponsorship agreement with Food Allergy Research and Education, Inc.
• Customer Concentration: The company faces concentration risk with a few large wholesale distributors and international partners.

Geographic Revenue Distribution:

• United States: $72.2 million (2025)
• Rest of world: $12.1 million (2025)
• Growth Markets: Europe, Asia (China, Japan), Canada, Australia, and New Zealand are targeted for market expansion through collaboration partners.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The market for emergency treatment of Type I allergic reactions is highly competitive and subject to rapid technological change. The epinephrine intra-muscular injectable market has historically grown by approximately 6.5% annually (2010-2023). There is a significant unmet need for needle-free epinephrine due to limitations of existing injectable products, including portability, patient reluctance to use, needle apprehension, dosing errors, and safety concerns. The chronic urticaria market, a potential future indication for neffy, is estimated to include approximately 1.5 million diagnosed patients in the U.S., with about half experiencing frequent flares, representing a potential annual market opportunity exceeding $2.0 billion.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors (Epinephrine Intra-muscular Injectable Products):

• Viatris, Inc.: EpiPen
• Teva Pharmaceuticals, Inc.: Generic versions of EpiPen
• Amneal Pharmaceuticals, Inc.: Adrenaclick
• Kaleo, Inc.: Auvi-Q
• Sandoz, Inc. (a Novartis division): Symjepi

Emerging Competitive Threats:

• Other Intranasal Candidates: Bryn Pharma, Nasus Pharma Ltd., Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.), Orexo AB, and Belhaven BioPharma are developing higher-dose intranasal epinephrine product candidates.
• Sublingual Candidates: Aquestive Therapeutics, Inc. is developing Anaphylm (a sublingual prodrug of epinephrine), which recently received a Complete Response Letter from the FDA due to application concerns.

Competitive Response Strategy: ARS Pharmaceuticals, Inc. aims to maintain its competitive advantage by emphasizing neffy's unique needle-free delivery, ease of use, and improved patient experience, which addresses significant limitations of existing injectable products. The company is investing heavily in direct-to-consumer marketing to drive patient demand and is actively working to secure broad insurance coverage and competitive pricing. Strategic expansion of its sales force and professional education efforts target high-prescribing physicians. The company is also pursuing additional indications, such as chronic urticaria, to broaden neffy's market opportunity and leverage real-world evidence to support its clinical effectiveness.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Dependence on neffy: The company is highly dependent on the successful commercialization of neffy; failure to achieve commercial success would materially adversely affect its business and stock price.
• Market Acceptance: neffy may fail to gain sufficient market acceptance by allergists, pediatricians, other physicians, patients, caregivers, and third-party payors, limiting commercial success.
• Market Size: The estimated market opportunity for neffy may be smaller than anticipated, leading to lower-than-expected future product revenues.
• Coverage & Reimbursement: Inability to achieve and maintain adequate levels of third-party payor coverage and reimbursement for neffy on reasonable pricing terms could severely hinder its commercial success.
• Competition: Existing and emerging competitive products, including generic versions of epinephrine autoinjectors and other intranasal/sublingual candidates, may reduce or eliminate neffy's commercial opportunity.
• Generic Competition: The company has not received U.S. non-patent marketing exclusivity for neffy. Lupin, Inc. has filed Abbreviated New Drug Applications ("ANDAs") for generic versions of neffy 2 mg and 1 mg, leading to patent infringement lawsuits. Unfavorable outcomes in these lawsuits could result in earlier generic competition.
• International Approvals: Obtaining regulatory approval in one jurisdiction does not guarantee success in others, and delays or failures in foreign regulatory processes could negatively impact global commercialization.
• Post-Approval Data: Real-world use of neffy in a larger patient population may not be consistent with clinical study results, potentially leading to label changes, reduced sales, or market withdrawal.
• Off-label Promotion: Risk of regulatory enforcement actions (e.g., untitled letters from the Department of Human & Health Services regarding TV advertisements) for alleged improper promotion of off-label uses.
• Social Media Risks: Increasing use of social media platforms presents risks related to non-compliance with regulations, adverse impact on clinical trial enrollment, and negative or inaccurate public commentary.

Technology Disruption:

• The rapid pace of technological change in the industry means new treatment methods could render neffy non-competitive or obsolete.

Customer Concentration:

• A significant portion of accounts receivable and gross product sales are concentrated among a few wholesale distributors and pharmacies, posing a concentration risk.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Complete reliance on third-party contract manufacturing organizations ("CMOs") for all raw materials, drug substance, drug product, labeling, and packaging.
• Supply Interruptions: Risks of shortages, interruptions, or price fluctuations if third-party suppliers discontinue products or fail to meet contractual obligations.
• Regulatory Approval of Suppliers: Changes in raw material suppliers require additional regulatory approvals, which can be time-consuming and costly.
• Third-Party Manufacturer Compliance: CMOs may fail to comply with current Good Manufacturing Practice ("cGMP") regulations or other regulatory requirements, leading to quality issues, production delays, or regulatory sanctions.
• Geographic Concentration: Production and development are concentrated at a few locations (e.g., Renaissance Lakewood, LLC in New Jersey), making the company vulnerable to business interruptions from natural disasters, industrial accidents, or other unforeseen events.

Capacity Constraints:

• Not explicitly detailed as a current risk, but inherent in reliance on third-party manufacturing.

Financial & Regulatory Risks

Market & Financial Risks:

• Fluctuating Results: Operating results and sales are expected to fluctuate, making future performance difficult to predict.
• Significant Losses: The company has incurred significant losses since inception, with an accumulated deficit of $294.6 million as of December 31, 2025, and expects to continue incurring losses.
• Additional Funding: May require additional funding beyond current resources; inability to raise capital on favorable terms could force delays or reductions in product development or commercialization efforts.
• Dilution & Restrictions: Future equity offerings could dilute stockholder interests, and debt financing (e.g., the Credit Agreement) may impose restrictive covenants that limit operational flexibility.
• Debt Repayment: The company may be required to repay its outstanding indebtedness under the Credit Agreement earlier than expected if an event of default occurs, potentially at a time when it lacks sufficient capital.
• Tax Law Changes: Changes in U.S. federal, state, and local tax laws (e.g., the One Big Beautiful Bill Act) could adversely affect the company's business and financial condition.
• NOL Limitations: The ability to use net operating loss carryforwards and other tax attributes may be limited due to ownership changes under Internal Revenue Code Sections 382 and 383.

Regulatory & Compliance Risks:

• Ongoing Regulatory Obligations: neffy is subject to continuous regulatory review and post-marketing obligations by the FDA, EMA, and other authorities, including reporting, manufacturing standards, and promotional restrictions.
• Post-Marketing Restrictions: Later discovery of unknown side effects or manufacturing problems could lead to post-marketing restrictions, product recalls, or withdrawal from the market.
• Healthcare Laws: Business activities are subject to federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA, Physician Payments Sunshine Act), with non-compliance potentially leading to significant penalties.
• Healthcare Reform: Ongoing and future legislative and regulatory changes in healthcare (e.g., ACA, Medicare Drug Price Negotiation Program) could increase commercialization costs and affect product pricing.
• FDA Disruptions: Disruptions at the FDA, such as budget constraints or workforce reductions, could delay regulatory reviews and approvals.
• Foreign Price Controls: Governments outside the U.S. may impose strict price controls, potentially reducing revenues from international sales.
• FCPA & Anti-Bribery: Operations in foreign countries are subject to the U.S. Foreign Corrupt Practices Act ("FCPA") and similar anti-bribery laws, with violations potentially leading to fines, sanctions, and reputational damage.
• Export Controls & Trade Sanctions: Compliance with U.S. and foreign export controls, trade sanctions, and import laws is required, and non-compliance could harm international sales.
• Data Privacy & Security: Subject to stringent and evolving U.S. and foreign data privacy and security laws (e.g., HIPAA, CCPA, GDPR, PIPL), with non-compliance risking regulatory investigations, litigation, fines, and reputational harm. Increased risks from remote work and the use of AI technologies.
• Legal Proceedings: The company is involved in material legal proceedings, including patent infringement lawsuits against Lupin, Inc. and litigation with AptarGroup, Inc. related to trade secrets and antitrust. These proceedings are costly, time-consuming, and their outcomes are unpredictable.

Geopolitical & External Risks

Geopolitical Exposure:

• Geographic Dependencies: Reliance on international third-party licensees and assignees for ex-U.S. development and commercialization means their performance directly impacts the company's financial results.
• Trade Relations: International trade policies, including tariffs, sanctions, and trade barriers, particularly those affecting the European Union and pharmaceutical products, could materially increase costs, disrupt the supply chain, and reduce margins.
• Sanctions & Export Controls: U.S. export control laws and economic sanctions could limit the ability to ship products to certain countries or parties, impacting international sales.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Intranasal Epinephrine Technology: Focus on developing and commercializing neffy, a proprietary composition of epinephrine with the Intravail absorption enhancer for needle-free intranasal delivery. This technology aims to provide injection-like absorption at low doses (2 mg or 1 mg) comparable to 0.3 mg or 0.15 mg injections.
• Innovation Pipeline: The company is conducting clinical studies to expand neffy's labeling to other Type I allergy conditions, specifically chronic spontaneous urticaria. A Phase 2b randomized, placebo-controlled outpatient clinical trial for chronic spontaneous urticaria was initiated in Q2 2025, with interim data anticipated in H2 2026 and a potential pivotal efficacy study in mid-2027.

Intellectual Property Portfolio:

• Patent Strategy: ARS Pharmaceuticals, Inc. owns, co-owns, or exclusively licenses a global intellectual property portfolio to protect neffy and its intranasal epinephrine technology product candidates.
• Patent Holdings (as of December 31, 2025):
  • Eight issued U.S. patents.
  • Granted patents in Australia, Canada, China, Hong Kong, Israel, Japan, Mexico, Singapore, South Korea, and over thirty member states of the European Patent Organization (including the U.K.).
  • Three pending U.S. patent applications.
  • One pending international patent application.
  • Sixteen pending foreign patent applications.
  • One pending U.S. provisional patent application directed to intranasal epinephrine formulations and methods of their use.
• Patent Expiration: These issued patents and pending applications are expected to expire as early as 2038, absent any patent term adjustments.
• Licensing Programs: The company has an exclusive, worldwide license agreement with Aegis Therapeutics, LLC for the Intravail drug delivery technology.
• IP Litigation: The company is involved in patent infringement lawsuits against Lupin, Inc. following ANDA submissions for generic neffy 2 mg and 1 mg. It is also involved in litigation with AptarGroup, Inc. concerning alleged trade secret misappropriation, contract breaches, and antitrust claims.

Technology Partnerships:

• Aegis Therapeutics, LLC: Provides an exclusive, worldwide, sublicensable license for the Intravail drug delivery technology, a key component of neffy.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's founders (Richard Lowenthal, Robert Bell, Sarina Tanimoto) remain in key executive roles. The management team has extensive experience in drug development and commercialization, particularly with nasal spray products.

Board Composition: The Board of Directors includes Pratik Shah, Ph.D. (Chairman), Peter Kolchinsky, Ph.D., Rajeev Dadoo, Ph.D., Brenton L. Saunders, Phillip Schneider, Michael Kelly, Laura Shawver, Ph.D., Peter A. Thompson, M.D., and Saqib Islam, J.D. One board member is a controlling person of RA Capital Management, L.P.'s general partner. The audit committee is responsible for overseeing cybersecurity risk management processes.

Human Capital Strategy

Workforce Composition:

• Total Employees: 158 full-time employees and 5 part-time employees as of December 31, 2025.
• Headcount Growth: Increased significantly from 23 full-time and 5 part-time employees as of July 31, 2024, following FDA approval of neffy.
• Geographic Distribution: Not explicitly detailed.
• Skill Mix: 4 employees hold Ph.D. or M.D. degrees.

Talent Management: Acquisition & Retention:

• Hiring Strategy: The company expanded its sales force and made additional hires in general and administrative, medical, commercial, sales and marketing, and operations. It plans to further expand its internal sales force to approximately 150 individuals beginning in Q2 2026.
• Retention Metrics: Not explicitly detailed.
• Employee Value Proposition: Not explicitly detailed.

Diversity & Development:

• Not explicitly detailed.

Environmental & Social Impact

Environmental Commitments:

• Not explicitly detailed in the provided filing.

Supply Chain Sustainability:

• Not explicitly detailed in the provided filing.

Social Impact Initiatives:

• Community Investment: ARS Pharmaceuticals, Inc. has a corporate sponsorship agreement with Food Allergy Research and Education, Inc., with $6.0 million in remaining payment obligations as of December 31, 2025.
• Product Impact: The company supports the "neffy inSchools" program, through which over 9,000 schools have opted into receiving two cartons of neffy at no cost, accompanied by school nurse education about the product.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Not explicitly detailed in the filing.
• Economic Sensitivity: Not explicitly detailed in the filing.
• Industry Cycles: Not explicitly detailed in the filing.

Planning & Forecasting:

• The company expects its timing of sales and results of operations to fluctuate for the foreseeable future, particularly during the ongoing commercial launch of neffy, making future performance difficult to predict. Product revenues are also expected to fluctuate.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• U.S. FDA: ARS Pharmaceuticals, Inc. is subject to extensive FDA regulation under the Federal Food, Drug and Cosmetic Act ("FDCA"), including requirements for investigational new drug ("IND") applications, Good Laboratory Practice ("GLP") for preclinical tests, Good Clinical Practice ("GCP") for human clinical trials, and current Good Manufacturing Practice ("cGMP") for manufacturing. neffy was approved via the Section 505(b)(2) regulatory pathway. Post-approval, the company is subject to ongoing obligations including adverse event reporting, product sampling and distribution, and strict regulations on marketing, labeling, advertising, and promotion. The Pediatric Research Equity Act ("PREA") requires pediatric assessments for most new drugs.
• European Medicines Agency ("EMA") / European Commission ("EC"): In the EU, medicinal products require marketing authorization ("MA") through procedures like the centralized procedure administered by the EMA. Clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014 ("CTR"). EURneffy 2 mg received marketing authorization from the EC, and EURneffy 1 mg received a positive CHMP opinion. The EU provides 8 years of data exclusivity and 2 years of market exclusivity for new chemical entities. Manufacturing requires authorization and compliance with EU cGMP standards.
• United Kingdom ("U.K.") Medicines and Healthcare products Regulatory Agency ("MHRA"): Post-Brexit, the MHRA is the standalone regulator. The UK regulatory framework for clinical trials is evolving, with legislative amendments aligning closer to the EU CTR. Marketing authorizations are governed by national procedures or International Recognition Procedures ("IRP").
• Combination Products: neffy is a drug and delivery device combination product. In the U.S., it is reviewed under drug approval processes but is subject to cGMP requirements for both drugs and devices. In the EU, it is regulated as a medicinal product, with the General Safety and Performance Requirements ("GSPRs") of the Medical Devices Regulation ("MDR") applicable to the device component.

Trade & Export Controls:

• The company's products and business activities are subject to U.S. and foreign export controls, trade sanctions, and import laws and regulations. Compliance is required for international sales and operations.

Legal Proceedings:

• Aptar Litigation: AptarGroup, Inc. and Aptar France SAS filed a lawsuit in March 2025 alleging Defend Trade Secrets Act violations, trade secret misappropriation, and contract breaches. ARS Pharmaceuticals, Inc. filed a motion to dismiss and subsequently filed an antitrust lawsuit against AptarGroup, Inc. in September 2025.
• Lupin Lawsuits: ARS Pharmaceuticals, Inc. filed patent infringement lawsuits against Lupin, Inc. in August 2025 and February 2026, following Lupin's ANDA submissions for generic versions of neffy 2 mg and 1 mg, respectively. These lawsuits seek permanent injunctions.
• European Patent Office Opposition: An opposition was filed against EP 3678649 (a patent for neffy's nasal spray formulation) in July 2023. The EPO upheld the patent's validity in October 2025, but the opponent filed an appeal in December 2025.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 0.0% for the year ended December 31, 2025.
• Geographic Tax Planning: Files income tax returns in the United States, various states, and Ireland.
• Tax Reform Impact: The company has evaluated the impact of the One Big Beautiful Bill Act ("OBBBA"), signed into law in July 2025, which enacts significant changes to U.S. tax laws, including provisions affecting domestic research expenses, interest expense deductions, and bonus depreciation.
• Net Operating Losses ("NOLs"): As of December 31, 2025, the company had federal NOL carryforwards of $150.5 million (generated after 2017, carryforward indefinitely, limited to 80% of taxable income) and state NOL carryforwards of $16.7 million (some expiring in 2035, some indefinite).
• Research & Development Credits: Federal R&D credit carryforwards totaled $4.1 million (expiring in 2039) and state R&D credit carryforwards totaled $1.0 million (some expiring in 2038, some indefinite).
• Valuation Allowance: A full valuation allowance of $73.4 million was maintained against net deferred tax assets as of December 31, 2025, due to uncertainty regarding their realization.
• Unrecognized Tax Benefits: The company had $7.3 million in unrecognized tax benefits as of December 31, 2025, with no accrued interest or penalties.
• NOL Limitations: Annual use of NOL and R&D credit carryforwards may be limited by Internal Revenue Code Sections 382 and 383 if an "ownership change" occurs.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: ARS Pharmaceuticals, Inc. maintains product liability insurance coverage of up to $10.0 million in aggregate, covering both commercial product liability and clinical trial liability. The company also maintains workers' compensation insurance.
• Risk Transfer Mechanisms: The company does not maintain insurance for environmental liability or toxic tort claims. Other specific risk transfer mechanisms are not explicitly detailed in the filing.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: The filing does not explicitly detail specific seasonal trends in demand for neffy or its product candidates.
• Economic Sensitivity: The filing does not explicitly detail specific economic sensitivities for the business.
• Industry Cycles: The filing does not explicitly detail specific industry cyclical patterns.

Planning & Forecasting:

• The company expects its timing of sales and results of operations to fluctuate for the foreseeable future, which may make it difficult to predict future performance from period to period. This is particularly true during the ongoing commercial launch of neffy.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• U.S. FDA: ARS Pharmaceuticals, Inc. operates under the extensive regulatory framework of the FDA, including the Federal Food, Drug and Cosmetic Act (FDCA). This involves rigorous requirements for Investigational New Drug (IND) applications, adherence to Good Laboratory Practice (GLP) for preclinical studies, Good Clinical Practice (GCP) for human clinical trials, and current Good Manufacturing Practice (cGMP) for manufacturing. neffy received approval via the Section 505(b)(2) regulatory pathway. Post-approval, the company faces ongoing obligations such as submitting safety and post-marketing reports, maintaining registration and listing, ensuring quality control, and complying with strict regulations on product distribution, promotion, advertising, and labeling. The Pediatric Research Equity Act (PREA) mandates pediatric assessments for most new drugs, and the FDA may require Risk Evaluation and Mitigation Strategies (REMS) or Boxed Warnings.
• European Medicines Agency (EMA) / European Commission (EC): In the EU, medicinal products require Marketing Authorization (MA), often through the centralized procedure overseen by the EMA. Clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014 (CTR). EURneffy 2 mg has received MA from the EC, and EURneffy 1 mg has received a positive CHMP opinion. The EU provides 8 years of data exclusivity and 2 years of market exclusivity for new chemical entities. Manufacturing requires authorization and compliance with EU cGMP standards. Post-authorization, the company must maintain pharmacovigilance systems and submit Risk Management Plans (RMPs).
• United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA): Following Brexit, the MHRA is the U.K.'s standalone regulator. The U.K. regulatory framework for clinical trials is evolving, with new legislative amendments aligning closer to the EU CTR. Marketing authorizations are obtained through national procedures or the International Recognition Procedures (IRP).
• Combination Products: neffy is a drug-device combination product. In the U.S., it is subject to cGMP requirements for both drug and device components. In the EU, it is regulated as a medicinal product, with the General Safety and Performance Requirements (GSPRs) of the Medical Devices Regulation (MDR) applicable to the device part.

Trade & Export Controls:

• The company's business activities and products are subject to U.S. and foreign export controls, trade sanctions, and import laws and regulations. Compliance with these requirements is critical for international sales and operations, and non-compliance could lead to penalties and harm international business.

Legal Proceedings:

• Aptar Litigation: AptarGroup, Inc. and Aptar France SAS filed a lawsuit in March 2025 against ARS Pharmaceuticals, Inc., alleging violations of the Defend Trade Secrets Act, misappropriation of trade secrets under New York state law, and breaches of contract. ARS Pharmaceuticals, Inc. filed a motion to dismiss and subsequently initiated an antitrust lawsuit against AptarGroup, Inc. in September 2025.
• Lupin Lawsuits: ARS Pharmaceuticals, Inc. filed patent infringement lawsuits against Lupin, Inc. in August 2025 and February 2026, following Lupin's Paragraph IV certification notice letters regarding Abbreviated New Drug Applications (ANDAs) for generic versions of neffy 2 mg and 1 mg, respectively. The company is seeking permanent injunctions to prevent generic market entry.
• European Patent Office Opposition: An opposition was filed by Aera A/S in July 2023 against European Patent EP 3678649, which covers a nasal spray formulation of epinephrine. The EPO upheld the patent's validity in October 2025, but the opponent filed a notice of appeal in December 2025.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The company reported an effective tax rate of 0.0% for the year ended December 31, 2025.
• Geographic Tax Planning: ARS Pharmaceuticals, Inc. files income tax returns in the United States, various states, and Ireland.
• Tax Reform Impact: The company has evaluated the impact of the One Big Beautiful Bill Act (OBBBA), signed into law in July 2025, which introduced significant changes to U.S. tax laws, including provisions related to the current deduction of domestic research expenses, limitations on interest expense deductions, and 100% bonus depreciation on eligible property acquired after January 19, 2025.
• Net Operating Losses (NOLs): As of December 31, 2025, the company had federal net operating loss carryforwards of $150.5 million (generated after 2017, carryforward indefinitely, but deductibility limited to 80% of taxable income) and state NOL carryforwards of $16.7 million (some beginning to expire in 2035, others carryforward indefinitely).
• Research & Development Credits: The company holds federal research and development credit carryforwards totaling $4.1 million (beginning to expire in 2039) and state R&D credit carryforwards of $1.0 million (some beginning to expire in 2038, others indefinite).
• Valuation Allowance: A full valuation allowance of $73.4 million was established against net deferred tax assets as of December 31, 2025, reflecting management's assessment that it is not "more likely than not" that these assets will be realized in the future.
• Unrecognized Tax Benefits: As of December 31, 2025, the company had $7.3 million in unrecognized tax benefits, with no significant accruals for interest or penalties related to uncertain tax positions.
• NOL Limitations: The company's NOL and credit carryforwards may be subject to annual limitations under Internal Revenue Code Sections 382 and 383 in the event of a cumulative change in ownership exceeding 50% within a three-year period.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: ARS Pharmaceuticals, Inc. maintains product liability insurance coverage of up to $10.0 million in aggregate, which covers both commercial product liability and clinical trial liability. The company also carries workers' compensation insurance to cover costs and expenses related to employee injuries.
• Risk Transfer Mechanisms: The company does not maintain insurance for environmental liability or toxic tort claims. Other specific risk transfer mechanisms are not explicitly detailed in the filing.